Description: <b>Crocetin</b> is a carotenoid pigment found in saffron (Crocus sativus) and has been studied for its potential anti-cancer properties. Research has shown that crocetin may have anti-tumor and anti-proliferative effects, inhibiting the growth of various types of cancer cells.<br>
Crocetin is a carotenoid dicarboxylic acid derived from saffron (Crocus sativus) and is a metabolite of crocin. It is lipophilic and more bioavailable than crocin. In cancer research, crocetin is studied mainly in preclinical models, where it appears to influence apoptosis, inflammation, angiogenesis, and redox signaling. It is not a primary cytotoxic chemotherapeutic, but a signaling and stress-modulating compound.<br>
<pre>
Mechanistic themes reported:
-NF-κB suppression
-PI3K/AKT pathway modulation
-MAPK signaling effects
-Apoptosis induction (mitochondrial pathway)
-Anti-angiogenic signaling (VEGF reduction)
-Redox modulation (context-dependent antioxidant / pro-oxidant behavior)
Evidence level: predominantly cell culture and animal models.
</pre>
Reported to modulate glycolytic metabolism and lactate production (model-dependent); LDH5 inhibition has been reported preclinically, but clinical relevance and achievable tumor exposure are not established.<br>
<br>
<br>
<p><b>Crocetin</b> — Crocetin is a saffron/gardenia-derived apocarotenoid dicarboxylic acid and the aglycone bioactive metabolite of crocin. It is formally a natural-product carotenoid derivative rather than an approved anticancer drug. Standard abbreviations include Cro and, less commonly, trans-crocetin or crocetic acid. It originates primarily from <i>Crocus sativus</i> stigma and <i>Gardenia jasminoides</i> fruit, with crocin serving as a glycosylated precursor that is hydrolyzed to crocetin after oral intake. In oncology, crocetin is best classified as a preclinical signaling, redox, metabolism, and apoptosis-modulating compound with limited direct human cancer-treatment evidence.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Mitochondrial apoptosis induction through Bax/Bcl-2 shift, caspase activation, mitochondrial membrane potential disruption, and cell-cycle checkpoint effects.</li>
<li>Suppression of inflammatory and survival signaling, especially NF-κB-linked cytokine, COX-2, VEGF, and invasion programs.</li>
<li>PI3K/AKT, MAPK, STAT3, SHH, and related growth-pathway modulation, with direction varying by cancer model.</li>
<li>Antiglycolytic activity through LDH5/LDHA-linked lactate metabolism effects; stronger as a preclinical metabolic hypothesis than as a clinically validated anticancer axis.</li>
<li>Anti-angiogenic and anti-invasive modulation, including VEGF, MMPs, EMT markers, and migration suppression in selected models.</li>
<li>Redox modulation, generally antioxidant/cytoprotective in normal-tissue injury models but context-dependent in cancer cells; NRF2/HO-1 activation is better supported in normal-cell injury models than as a core anticancer mechanism.</li>
<li>Adjunct chemosensitization, reported with vincristine and cisplatin in cell models, but not clinically established.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral crocin is poorly absorbed intact and is largely converted to crocetin by intestinal and microbial glycosidase activity. Crocetin itself appears in plasma after oral crocin or crocetin exposure, often as free crocetin and glucuronide conjugates, but poor solubility, formulation dependence, intestinal metabolism, and uncertain tumor-tissue exposure constrain translation.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many anticancer cell studies use crocetin in the approximate 50–800 µM range, with several key studies around 60–240 µM or higher. These concentrations likely exceed typical exposure from dietary saffron or ordinary oral supplement use, so in-vitro cytotoxic and chemosensitizing effects should be treated as high-concentration/preclinical unless supported by formulation-specific PK data.</p>
<p><b>Clinical evidence status:</b> Preclinical for oncology. There are cell-culture and animal tumor data, including pancreatic, colorectal, gastric, cervical/ovarian, prostate, and hepatocellular models, plus limited adjunct combination data. Human clinical evidence for isolated crocetin is mainly non-oncology or safety-oriented, while oncology-related human trials are more often crocin/saffron adjunctive or supportive-care contexts rather than crocetin as an anticancer therapy.</p>
<h3>Crocetin Cancer Mechanism Table</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Mitochondrial apoptosis and cell-cycle checkpoints</td>
<td>Bax ↑; Bcl-2 ↓; caspase-3/9 ↑; p21 ↑; G1/S/G2-M arrest ↑ (model-dependent)</td>
<td>Apoptosis ↓ in injury models; mitochondrial protection ↑ (context-dependent)</td>
<td>G</td>
<td>Apoptosis induction and cytostasis</td>
<td>Core anticancer mechanism across multiple models; normal-cell effects often move in the opposite protective direction under oxidative or inflammatory injury.</td>
</tr>
<tr>
<td>2</td>
<td>NF-κB inflammatory survival signaling</td>
<td>NF-κB ↓; IL-6 ↓; IL-8 ↓; COX-2 ↓; iNOS ↓; inflammatory transcription ↓</td>
<td>NF-κB-driven inflammation ↓</td>
<td>R, G</td>
<td>Anti-inflammatory tumor suppression</td>
<td>Central to anti-invasive and anti-angiogenic interpretations; strongest where inflammation-linked tumor progression is active.</td>
</tr>
<tr>
<td>3</td>
<td>PI3K / AKT and survival kinase signaling</td>
<td>p-AKT ↓ or pathway suppression ↑ (model-dependent); survival signaling ↓</td>
<td>p-AKT ↑ in some endothelial/cardioprotective injury models</td>
<td>R, G</td>
<td>Growth and survival pathway modulation</td>
<td>Direction is highly context-dependent; cancer-cell suppression should not be generalized to all normal tissues.</td>
</tr>
<tr>
<td>4</td>
<td>MAPK stress signaling</td>
<td>p38 MAPK ↑; ERK/JNK effects variable; migration ↓ in HCT-116 models</td>
<td>↔ or stress signaling normalization (context-dependent)</td>
<td>P, R, G</td>
<td>Stress-pathway reprogramming</td>
<td>Important in colorectal models, but direction and therapeutic implication vary by tumor genotype and drug context.</td>
</tr>
<tr>
<td>5</td>
<td>LDH5 / lactate metabolism</td>
<td>LDH5 activity ↓; LDHA protein ↓; lactate production ↓; glycolytic phenotype ↓ (model-dependent)</td>
<td>↔</td>
<td>R, G</td>
<td>Antiglycolytic pressure</td>
<td>Mechanistically attractive because LDH5 is a Warburg-metabolism target, but evidence is still mainly biochemical and preclinical.</td>
</tr>
<tr>
<td>6</td>
<td>Angiogenesis and VEGF axis</td>
<td>VEGF ↓; EGFR phosphorylation ↓; angiogenic signaling ↓</td>
<td>↔ or vascular protection ↑ in injury models</td>
<td>G</td>
<td>Anti-angiogenic support</td>
<td>Usually secondary to NF-κB, AKT, EGFR, and inflammatory pathway changes rather than a uniquely direct anti-VEGF drug-like mechanism.</td>
</tr>
<tr>
<td>7</td>
<td>Migration / invasion and EMT</td>
<td>MMP-2 ↓; MMP-9 ↓; uPA ↓; N-cadherin ↓; β-catenin ↓; E-cadherin ↑</td>
<td>↔</td>
<td>G</td>
<td>Anti-invasive phenotype</td>
<td>Relevant to metastasis biology but mostly based on in-vitro migration/invasion and selected xenograft models.</td>
</tr>
<tr>
<td>8</td>
<td>ROS and oxidative stress balance</td>
<td>ROS effects mixed; oxidative stress ↓ in some melanoma/cancer models; apoptosis may occur without a simple ROS ↑ pattern</td>
<td>ROS ↓; MDA ↓; lipid peroxidation ↓; SOD/GPx/GSH defenses ↑</td>
<td>P, R, G</td>
<td>Redox buffering and stress modulation</td>
<td>More clearly cytoprotective in normal-cell injury models than selectively pro-oxidant in cancer. Not a universal cancer ROS increaser.</td>
</tr>
<tr>
<td>9</td>
<td>NRF2 / HO-1 antioxidant response</td>
<td>↔ or uncertain; cancer-specific NRF2 direction is not well established</td>
<td>NRF2 ↑; HO-1 ↑ in oxidative/inflammatory injury models</td>
<td>R, G</td>
<td>Normal-tissue cytoprotection</td>
<td>Relevant as a protective/stress-response axis. Because sustained NRF2 activation can support therapy resistance in some cancers, this is a context-sensitive translation issue.</td>
</tr>
<tr>
<td>10</td>
<td>STAT3 / JAK / Src signaling</td>
<td>STAT3 activation ↓; nuclear accumulation ↓; upstream Src/JAK signaling ↓ (reported in hepatocellular models)</td>
<td>↔</td>
<td>R, G</td>
<td>Proliferation and inflammatory transcription suppression</td>
<td>Secondary but potentially meaningful where STAT3-driven inflammation/survival signaling is dominant.</td>
</tr>
<tr>
<td>11</td>
<td>SHH / Gli cancer stem and gastric signaling</td>
<td>SHH ↓; Gli1 ↓; DCLK1 ↓; cancer stem phenotype ↓ (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Stemness and developmental pathway modulation</td>
<td>Potentially relevant in pancreatic and gastric contexts, but not yet a broad validated crocetin mechanism.</td>
</tr>
<tr>
<td>12</td>
<td>Chemosensitization</td>
<td>Vincristine sensitivity ↑; cisplatin-induced apoptosis ↑ in selected models</td>
<td>Normal-tissue protection possible but not established for oncology treatment protocols</td>
<td>G</td>
<td>Adjunct sensitization</td>
<td>Combination evidence is preclinical. Antioxidant and NRF2-linked effects make timing, concentration, and chemotherapy mechanism important.</td>
</tr>
<tr>
<td>13</td>
<td>Clinical Translation Constraint</td>
<td>Effective in-vitro concentrations often high; tumor exposure uncertain; human oncology efficacy not established</td>
<td>Generally tolerated in limited human non-oncology studies, but cancer-treatment safety is not established</td>
<td>G</td>
<td>Evidence and delivery limitation</td>
<td>Key constraints are poor solubility, formulation dependence, metabolism from crocin to crocetin, uncertain achievable tumor concentration, and lack of definitive anticancer trials.</td>
</tr>
</table>
<p><b>Time-Scale Flag (TSF):</b> P / R / G</p>
<ul>
<li><b>P</b>: 0–30 min (early redox and signaling interactions)</li>
<li><b>R</b>: 30 min–3 hr (NF-κB / PI3K / MAPK modulation)</li>
<li><b>G</b>: >3 hr (apoptosis, angiogenesis, and phenotype-level outcomes)</li>
</ul>
<br>
<br>
<p><b>Crocetin and Alzheimer’s disease context</b> — Crocetin is relevant to AD mainly as part of the saffron/crocin/crocetin evidence cluster rather than as a clinically established isolated AD drug. Mechanistic support includes antioxidant protection, anti-inflammatory signaling, Aβ-related effects, AChE inhibition signals from saffron constituents, ER-stress/apoptosis reduction, and possible BBB/gut-microbiome-mediated effects. Human RCT evidence is stronger for saffron extract than for purified crocetin.</p>
<h3>Crocetin AD-Relevant Mechanism Table</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Oxidative stress and lipid peroxidation</td>
<td>ROS ↓; MDA ↓; SOD/GPx/GSH ↑</td>
<td>P, R, G</td>
<td>Neuroprotection</td>
<td>Most consistent non-cancer mechanism; often demonstrated in injury or neurodegeneration models using saffron, crocin, or crocetin-related exposure.</td>
</tr>
<tr>
<td>2</td>
<td>Neuroinflammation</td>
<td>NF-κB ↓; TNF-α ↓; IL-1β ↓; inflammatory tone ↓</td>
<td>R, G</td>
<td>Anti-inflammatory support</td>
<td>Likely contributes to cognitive and neuroprotective outcomes, but source specificity may vary between saffron extract, crocin, and crocetin.</td>
</tr>
<tr>
<td>3</td>
<td>Aβ aggregation / amyloid burden</td>
<td>Aβ aggregation ↓; amyloid toxicity ↓ (model-dependent)</td>
<td>G</td>
<td>Protein aggregation modulation</td>
<td>Relevant for AD indexing, but human clinical claims should be tied to saffron/crocin trial evidence rather than isolated crocetin unless directly tested.</td>
</tr>
<tr>
<td>4</td>
<td>Cholinergic signaling</td>
<td>AChE ↓; ChAT ↑ (reported)</td>
<td>R, G</td>
<td>Neurotransmission support</td>
<td>AChE inhibition is plausible for saffron constituents; compound-specific potency and clinical relevance require careful source attribution.</td>
</tr>
<tr>
<td>5</td>
<td>ER stress and apoptosis</td>
<td>CHOP ↓; GRP78/BiP ↓; caspase-3 ↓; Bax ↓; Bcl-2 ↑</td>
<td>G</td>
<td>Stress and cell-death reduction</td>
<td>Protective direction is opposite to the desired cancer-cell apoptosis direction, so disease context must be explicit.</td>
</tr>
<tr>
<td>6</td>
<td>PK / CNS exposure constraint</td>
<td>Crocin → crocetin; plasma crocetin ↑; BBB exposure uncertain</td>
<td>R, G</td>
<td>Translation constraint</td>
<td>Recent metabolism data support intestinal conversion to crocetin, but direct brain exposure and active metabolites remain incompletely resolved.</td>
</tr>
</table>
<p><b>Time-Scale Flag (TSF):</b> P / R / G</p>
<ul>
<li><b>P</b>: 0–30 min (early redox and signaling interactions)</li>
<li><b>R</b>: 30 min–3 hr (NF-κB / PI3K / MAPK modulation)</li>
<li><b>G</b>: >3 hr (apoptosis, angiogenesis, and phenotype-level outcomes)</li>
</ul>